{"id":10859,"date":"2025-12-02T14:35:51","date_gmt":"2025-12-02T05:35:51","guid":{"rendered":"https:\/\/rightfoundation.kr\/en\/?p=10859"},"modified":"2025-12-03T09:39:59","modified_gmt":"2025-12-03T00:39:59","slug":"eubiologics-typhoid-conjugate-vaccine-shows-non-inferior-efficacy-in-phase-3-africa-trial","status":"publish","type":"post","link":"https:\/\/rightfoundation.kr\/en\/eubiologics-typhoid-conjugate-vaccine-shows-non-inferior-efficacy-in-phase-3-africa-trial\/","title":{"rendered":"EuBiologics\u2019 typhoid conjugate vaccine shows non-inferior efficacy in phase 3 Africa trial"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"10859\" class=\"elementor elementor-10859\">\n\t\t\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-22110e80 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"22110e80\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7581e584\" data-id=\"7581e584\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-79c9ffeb elementor-widget elementor-widget-stad_for_elementor_heading\" data-id=\"79c9ffeb\" data-element_type=\"widget\" data-widget_type=\"stad_for_elementor_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\r\n\t<div class=\"stad-heading stad-heading-single-content stad-padding-0 stad-margin-0\">\t\t<span class=\"stad-heading-single-content-text stad-heading-content-text stad-inline-block\">\r\n\t\t\t\t\t\t\t<span class=\"stad-heading-single-content-text-content\">EuBiologics\u2019 typhoid conjugate vaccine shows non-inferior efficacy in phase 3 Africa trial<\/span>\r\n\t\t\t\t\t<\/span>\r\n\t<\/div>\t\r\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5c9be6c elementor-widget elementor-widget-stad_for_elementor_heading\" data-id=\"5c9be6c\" data-element_type=\"widget\" data-widget_type=\"stad_for_elementor_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\r\n\t<div class=\"stad-heading stad-heading-single-content stad-padding-0 stad-margin-0\">\t\t<span class=\"stad-heading-single-content-text stad-heading-content-text stad-inline-block\">\r\n\t\t\t\t\t\t\t<span class=\"stad-heading-single-content-text-content\">RIGHT Foundation has supported EuBiologics\u2019 typhoid conjugate vaccine development since 2021 and will provide total funding of approximately KRW 5.7 billion through 2026.<\/span>\r\n\t\t\t\t\t<\/span>\r\n\t<\/div>\t\r\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4161c14 elementor-widget elementor-widget-text-editor\" data-id=\"4161c14\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.12.1 - 02-04-2023 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p>Korean vaccine developer EuBiologics said it has published the phase 3 multinational clinical trial results for its typhoid conjugate vaccine, EuTYPH C Inj., in the December issue of the Lancet Global Health.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c4375b8 elementor-widget elementor-widget-image\" data-id=\"c4375b8\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.12.1 - 02-04-2023 *\/\n.elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=\".svg\"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block}<\/style>\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"800\" height=\"422\" src=\"https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2.jpg\" class=\"attachment-large size-large wp-image-10858\" alt=\"\" loading=\"lazy\" srcset=\"https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2.jpg 800w, https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2-768x405.jpg 768w, https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2-667x352.jpg 667w, https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2-650x343.jpg 650w, https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2-550x290.jpg 550w, https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2-460x243.jpg 460w, https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2-450x237.jpg 450w, https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2-350x185.jpg 350w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c3f7b44 elementor-widget elementor-widget-text-editor\" data-id=\"c3f7b44\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>The study, conducted in Senegal and Kenya with 2,219 participants aged six months to 45 years, demonstrated clear immunological non-inferiority compared to Typbar TCV, a World Health Organization (WHO) prequalification vaccine.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8f94986 elementor-widget elementor-widget-text-editor\" data-id=\"8f94986\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>The trial was carried out in collaboration with the international health organization PATH and funded by the RIGHT Foundation.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-50f4f94 elementor-widget elementor-widget-text-editor\" data-id=\"50f4f94\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>The company expects that the findings carry significant global credibility because the research was conducted directly in African countries where the vaccine is expected to be supplied.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f664717 elementor-widget elementor-widget-text-editor\" data-id=\"f664717\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>According to the paper, seroconversion rates in infants aged nine to twelve months reached 99.6 to 100 percent on day 28, showing responses equivalent to or better than those seen with the WHO prequalified comparator. No serious adverse events were reported in either group.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e2248fd elementor-widget elementor-widget-text-editor\" data-id=\"e2248fd\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>EuBiologics obtained export approval for EuTYPH C inj. from Korea&#8217;s Ministry of Food and Drug Safety (MFDS) earlier this year and submitted its WHO prequalification application in May. The review is underway.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bd9b11b elementor-widget elementor-widget-text-editor\" data-id=\"bd9b11b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>If approved, the vaccine will be eligible for Gavi and UNICEF procurement, enabling full-scale supply as early as the second half of 2026. The company has also participated in UNICEF awards and tender processes since August.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b3bfc7c elementor-widget elementor-widget-text-editor\" data-id=\"b3bfc7c\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>Typhoid fever affects more than seven million people globally each year and remains a major infectious disease in low income regions.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b1b1eb7 elementor-widget elementor-widget-text-editor\" data-id=\"b1b1eb7\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>Demand for typhoid conjugate vaccines has been rising particularly in Africa and South Asia. EuTYPH C inj. is built on EuBiologics\u2019 proprietary CRM197 carrier protein and produced using a high efficiency conjugation and manufacturing system that the company says provides a cost advantage over competing vaccines.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ed855ef elementor-widget elementor-widget-text-editor\" data-id=\"ed855ef\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>EuBiologics has already supplied more than 200 million doses of its Euvichol oral cholera vaccine series through UNICEF procurement channels.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-7b42229c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7b42229c\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-1a79e19b\" data-id=\"1a79e19b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f1d567a elementor-align-left elementor-mobile-align-left elementor-widget elementor-widget-button\" data-id=\"f1d567a\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t<a href=\"https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=29613\" target=\"_blank\" rel=\"nofollow\" class=\"elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-text\">Article<\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-217a68c1\" data-id=\"217a68c1\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5749a4b7 elementor-align-right elementor-mobile-align-left elementor-widget elementor-widget-button\" data-id=\"5749a4b7\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t<a href=\"\/en\/partner-news\/\" class=\"elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-text\">Partner News List<\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-54a5a5cf elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"54a5a5cf\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-341b078a\" data-id=\"341b078a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>EuBiologics\u2019 typhoid conjugate vaccine shows non-inferior efficacy in phase 3 Africa trial RIGHT Foundation has supported EuBiologics\u2019 typhoid conjugate vaccine development since 2021 and will provide total funding of approximately KRW 5.7 billion through 2026. Korean vaccine developer EuBiologics said it has published the phase 3 multinational clinical trial results for its typhoid conjugate vaccine,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":10858,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[9],"tags":[],"jetpack_featured_media_url":"https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2025\/12\/f-2.jpg","_links":{"self":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts\/10859"}],"collection":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/comments?post=10859"}],"version-history":[{"count":8,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts\/10859\/revisions"}],"predecessor-version":[{"id":10867,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts\/10859\/revisions\/10867"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/media\/10858"}],"wp:attachment":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/media?parent=10859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/categories?post=10859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/tags?post=10859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}